Why these 4 large-cap stocks HUL, TCS, JSW Infra, Glenmark Pharma will be in focus in today’s trade
Fast-moving consumer Goods(FMCG) major Hindustan Unilever Limited (HUL) is all set to have its first female Managing Director and Chief Executive Officer (CEO). Priya Nair will be the company’s new MD and CEO starting August 1. Rohit Jawa, the current Managing Director and Chief Executive Officer (CEO) who was with the company for over 37 years has decided to step down and will be leaving HUL. Rohit took over as the CEO and MD of HUL in 2023. TCS’ Q1 revenue declined 3.1 per cent in constant currency terms. In rupee terms, it was at Rs. 63,437 crore, up 1.3 per cent on the year. Net profit, at Rs. 12,760 crore, got the benefit of increased ‘other income’ and delayed wage hikes.
Tata Consultancy Services reported a 6 per cent rise in net profit in the first quarter of FY26 but lower-than-expected revenue as subdued discretionary spending and global geopolitical uncertainties led to demand contraction. In a post-earnings call, the management said it was too early to say when growth would resume. “The trend in delays in decision-making and project-starts with respect to discretionary spends has continued and intensified in this quarter,” said Chief Executive Officer K Krithivasan.
JSW Infrastructure informed the exchanges that Resolution Plan submitted by the company for NCR Rail Infrastructure Limited under the corporate insolvency resolution process of the Insolvency and Bankruptcy Code, 2016, has been approved by the Committee of Creditors and the Company has received a Letter of Intent (“LoI”) from the Resolution Professional on July 10. NCR Rail owns and operates a Private Freight Terminal (PFT) in Khurja, Uttar Pradesh, with six rail lines. The facility is strategically located about 90 km from New Delhi and about 40 km from the upcoming Jewar Airport. The facility also features two covered fully constructed and operational warehouses with an area of 0.2 million square feet. It also owns a land bank of 130 acres.
Glenmark Pharmaceutical’s wholly-owned subsidiary Ichnos Glenmark Innovation Inc (IGI) has signed an exclusive licensing agreement with US drugmaker AbbVie for IGI’s lead drug candidate ISB 2001 for an upfront payment of $700 million (estimated ₹6,000 crore). The drug candidate is in Phase I clinical trials and has shown promising outcomes in patients with relapsed / refractory multiple myeloma. It was developed using New York-based IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases. All future development will be undertaken by AbbVie, and IGI could receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.
Published on July 11, 2025
